8.91
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AVXL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$9.36
Offen:
$9.36
24-Stunden-Volumen:
921.45K
Relative Volume:
0.91
Marktkapitalisierung:
$801.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-43.16M
KGV:
-16.20
EPS:
-0.55
Netto-Cashflow:
$-29.31M
1W Leistung:
-6.99%
1M Leistung:
+8.79%
6M Leistung:
+15.71%
1J Leistung:
+131.43%
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Firmenname
Anavex Life Sciences Corporation
Sektor
Branche
Telefon
844-689-3939
Adresse
630 5TH AVENUE, NEW YORK
Vergleichen Sie AVXL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AVXL
Anavex Life Sciences Corporation
|
8.91 | 801.30M | 0 | -43.16M | -29.31M | -0.55 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2022-12-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2022-06-23 | Eingeleitet | Berenberg | Buy |
2021-09-23 | Eingeleitet | BTIG Research | Buy |
2020-12-16 | Bestätigt | H.C. Wainwright | Buy |
2020-09-28 | Eingeleitet | Ladenburg Thalmann | Buy |
2020-02-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-06-18 | Eingeleitet | Janney | Buy |
2018-05-16 | Fortgesetzt | Maxim Group | Buy |
2018-03-08 | Eingeleitet | ROTH Capital | Buy |
2018-02-13 | Bestätigt | Maxim Group | Buy |
2017-09-29 | Fortgesetzt | Noble Financial | Buy |
2017-02-07 | Eingeleitet | Noble Financial | Buy |
2016-03-29 | Eingeleitet | FBR Capital | Outperform |
Alle ansehen
Anavex Life Sciences Corporation Aktie (AVXL) Neueste Nachrichten
Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) vs. Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Taking on analysts’ expectations and winning: Anavex Life Sciences Corporation (AVXL) - Sete News
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by JPMorgan Chase & Co. - Defense World
Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment - marketscreener.com
Anavex Life Sciences Corporation (AVXL) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences Corporation [AVXL] Records 50-Day SMA of $8.86 - knoxdaily.com
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference | AVXL Stock News - GuruFocus
Anavex Showcases Breakthrough CNS Drug Portfolio: CEO Details Multiple Disease Targets at Citizens Conference - Stock Titan
Wells Fargo & Company MN Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Anavex Life Sciences Corporation’s Market Journey: Closing Strong at 9.31, Up 1.09 - DWinneX
Buying Buzz: Anavex Life Sciences Corporation [AVXL] Director Donhauser Peter D.O. purchases 2,835 shares of the company – Knox Daily - knoxdaily.com
AVXL overperforms with a 5.14 increase in share price - uspostnews.com
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board - The Manila Times
Harvard-Trained Alzheimer's Pioneer With 35,000-Patient Database Strengthens Anavex's Scientific Team - Stock Titan
Anavex Life Sciences Appoints Dr. Audrey Gabelle, MD, PhD To Scientific Advisory Board - citybiz
Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance
Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer’s Data ... By GuruFocus - Investing.com Canada
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by LPL Financial LLC - Defense World
Anavex Life Sciences Presents Novel Alzheimer Treatment Research at International Conference in Abu Dhabi - Nasdaq
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East - TradingView
Geode Capital Management LLC Has $20.14 Million Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. (NASDAQ:AVXL) Holdings Raised by Alliancebernstein L.P. - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences LawsuitAVXL - ACCESS Newswire
Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN
Wellington Management Group LLP Makes New $1.70 Million Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Raymond James Financial Inc. Acquires Shares of 15,584 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Prudential Financial Inc. Acquires Shares of 10,160 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Vanguard Group Inc. Sells 59,727 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Corebridge Financial Inc. Trims Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Four-Year Data on New Drug for Early AD Positive - streetwisereports.com
Biotech Company Finds High-Impact Alzheimer's Therapy in Europe - streetwisereports.com
Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at HC Wainwright - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at D. Boral Capital - Defense World
Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years - Benzinga
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease - The Manila Times
Breakthrough: New Alzheimer's Drug Cuts Cognitive Decline Over 4 Years in Clinical Trial - Stock Titan
Class Action Filed Against Anavex Life Sciences Corporation (AVXL) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Anavex Life Sciences Corporation (AVXL)May 13, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact Levi & Korsinsky about pending Class ActionAVXL - ACCESS Newswire
AVXL’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Commonwealth Equity Services LLC Buys 7,285 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at HC Wainwright - Defense World
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Anavex Showcases Breakthrough CNS Therapies: CEO Details Pipeline at Major Healthcare Conference - Stock Titan
Heartland Advisors Inc. Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
19,558 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Acquired by Proficio Capital Partners LLC - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Trading Down 3.2%Here's Why - MarketBeat
AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Finanzdaten der Anavex Life Sciences Corporation-Aktie (AVXL)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):